New drug targets scarring in Crohn's – first look in humans
Knowledge-focused
Ongoing
This early-phase study tests an experimental drug called PALI-2108 in a small group of people with fibrostenotic Crohn's disease, a condition where the gut becomes scarred and narrow. The main goal is to see how the drug affects inflammation and scarring at the molecular level by…
Phase: PHASE1 • Sponsor: Palisade Bio • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC